Onychogryphosis
Methodology & AI Transparency ⓘ
Onychogryphosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Onychogryphosis is an ICD-10-CM indexed diagnosis (L60.2) within Hair Loss, Alopecia & Scalp Conditions.
- 2 Real-world patient consensus: Mapped to Hair Loss, Alopecia & Scalp Conditions under ICD-10-CM L60.2 for Onychogryphosis clinical workups.
- 3 Typical cash cost range: Clinicians assessing Onychogryphosis focus on shortened anagen growth in Onychogryphosis (L60.2: phase) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Onychogryphosis: 25-Hydroxy Vitamin D in Onychogryphosis (L60.2: & Zinc) (25(OH)D 45 – 70 ng/mL (L60.2)) and Total/Free Testosterone & in Onychogryphosis (L60.2: DHEA-S (if androgenic)).
Ask our AI Specialists anything about Onychogryphosis
What Is Onychogryphosis?
Onychogryphosis is an ICD-10-CM indexed diagnosis (L60.2) within Hair Loss, Alopecia & Scalp Conditions. Clinical evaluation centers on nutritional/endocrine lab panel in Onychogryphosis (L60.2: (ferritin) alongside serial 25-Hydroxy Vitamin D in Onychogryphosis (L60.2: & Zinc) tracking (25(OH)D 45 – 70 ng/mL (L60.2)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Onychogryphosis (ICD-10 L60.2) is driven by shortened anagen growth in Onychogryphosis (L60.2: phase); specialists in Hair Loss, Alopecia & Scalp Conditions monitor Total/Free Testosterone & in Onychogryphosis (L60.2: DHEA-S (if androgenic)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Onychogryphosis (L60.2): discrete smooth circular in Onychogryphosis (L60.2: patches of sudden)
- • Secondary Onychogryphosis clinical sign: thickened, discolored, brittle, in Onychogryphosis (L60.2: or subungually lifting)
- • Symptom flares in Onychogryphosis correlating with 25-Hydroxy Vitamin D in Onychogryphosis (L60.2: & Zinc) deviation outside 25(OH)D 45 – 70 ng/mL (L60.2)
- • Functional hair & scalp impact requiring nutritional/endocrine lab panel in Onychogryphosis (L60.2: (ferritin) evaluation (L60.2)
Onychogryphosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L60.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Hair Loss, Alopecia & Scalp Conditions | NLM Clinical Tables |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Onychogryphosis (L60.2: & Zinc) | 25(OH)D 45 – 70 ng/mL (L60.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total/Free Testosterone & in Onychogryphosis (L60.2: DHEA-S (if androgenic)) | Age/sex physiological range (L60.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin [Onychogryphosis L60.2] | 70 – 150 ng/mL (L60.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Onychogryphosis
Treatment selection for Onychogryphosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Onychogryphosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Photobiomodulation for the treatment of androgenetic hair: What a 795-Participant Study Found Using hair density (hairs/cm 2 ) as a measure of efficacy, the standardized mean difference (SMD) was 1.02 (95% CI: 0.68, 1.36) in favor of treatment over control (15 studies, pooled N = 795, p p = .08). The Journal of dermatological treatment • 2021-09-15 • Meta-Analysis | N = 795 | 91/100 | PMID 31746251 ↗ |
| Can This Approach Help? Inside the Latest Research on Androgenetic hair loss in the female. Treatment with 2% skin-applied minoxidil Applied to the skin minoxidil was significantly more effective than placebo in the treatment of female androgenetic hair loss. Archives of dermatology • 1994-03-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 8129407 ↗ |
| Can This Approach Help? Inside the Latest Research on Low-level light therapy using a helmet-type device for the treatment of LLLT showed a significant effect on increasing hair density in patients with androgenetic hair loss. Medicine • 2020-07-17 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 32702878 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of carboxytherapy in hair Carboxytherapy seems to be a promising therapeutic option for patchy AA and could be helpful as an add-on treatment of AGA but more than 6 sessions are required and adjuvants are recommended for maintenance of the results. Journal of cosmetic dermatology • 2018-12-15 • Randomized Controlled Trial | N = 80 | 88/100 | PMID 29460509 ↗ |
| Can This Approach Help? Inside the Latest Research on Fractional CO 2 Laser and Minoxidil in the Treatment of hair loss Areata, A Applied to the skin minoxidil 5% solution either alone or in combination with FCO 2 laser could be considered a safe and tolerable method for AA treatment. Lasers in surgery and medicine • 2025-02-15 • Randomized Controlled Trial | N = 150 | 88/100 | PMID 39789748 ↗ |
Onychogryphosis Patient Community & “People Like Me” Threads
Filter Onychogryphosis community threads and patient logs by age, biological sex, dosage, and treatment duration.